Thomas J. Polascik, MD, FACS

Thomas J. Polascik, MD, FACS

Duke University Medical Center

Durham, North Carolina

Thomas J. Polascik, MD, FACS, is Professor of Surgery at Duke University Medical Center and the Director of Surgical Technology at the Duke Prostate and Urological Cancer Center. He is the Founder and Co-Director of the International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer, which began at Duke in 2008. Dr. Polascik is the Editor of Imaging and Focal Therapy of Early Prostate Cancer. He is Founder and President of the Focal Therapy Society, as well as Director of Duke’s Society of Urologic Oncology Fellowship Training Program and the Genitourinary Program on Focal Therapy at the Duke Cancer Institute. He is the Medical Director of Duke’s Men’s Health Initiative Screening Event and is a governing member of several medical boards and societies. His clinical and research interests focus on prostate and kidney cancer. He has authored over 350 peer-reviewed manuscripts and book chapters.

Disclosures:

Consultant for Angiodynamics

Talks by Thomas J. Polascik, MD, FACS

Prostate Cryoablation: Tips and Tricks

Prostate Cryoablation: Tips and Tricks

Posted by | Mar 2020

Thomas J. Polascik, MD, FACS, a professor of urology at the Duke Cancer Institute, gives an overview of tips and tricks for successful cryoablation of the prostate while avoiding preventable complications from the procedure. He discusses common areas of complication and injury during cryoablation, including sphincteric incontinence, rectal fistula, and urethral slough, as well as the possibility of incomplete ablation resulting in PSA recurrence. Dr. Polascik then outlines common reasons for injury or incomplete cover to the prostate, urethra, rectum, and sphincter, as well as techniques to ensure a successful cryoablation surgery.

Read More
Integration of Germline Testing in Prostate Cancer Screening

Integration of Germline Testing in Prostate Cancer Screening

Posted by | Nov 2019

Thomas J. Polascik, MD, FACS, surveys the current status of germline testing for prostate cancer in screening populations, and explains how his institution, Duke University, has been advancing research in this area. He discusses current studies measuring the ability of germline testing to predict outcomes, highlights the Duke algorithm for when and whom to test, and describes challenges for integrating germline testing into the current model of prostate cancer screening.

Read More

Join the GRU Community

- Why Join? -